FDA
-
-
-
-
-
-
-
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins
-
-
-
-
-
-
-
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance
-
-
-
-
-
-
-
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
-
-
-
-
-
-
-
Evolus (EOLS) Reports Prelim Q4 Results
-
-
-
-
-
-
-
Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®
-
-
-
-
-
-
-
Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”
-
-
-
-
-
-
-
Evolus to Report First Quarter 2022 Results and Provide Business Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

